comparemela.com

Latest Breaking News On - Consortium phase - Page 1 : comparemela.com

Clinical trial may change the paradigm of care for patients with ALK-driven high-risk neuroblastoma

In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.

Researchers find lorlatinib to be safe and effective treatment for high-risk neuroblastoma

In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.